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The cellular interaction of proteins modified with advanced glycation end-products (AGEs) is believed to induce several different biological
responses, which are involved in the development of diabetic vascular complications. We report here that the ratio of protein glycation is
implicated in its ligand activity to scavenger receptors. Although highly-modified AGE-bovine serum albumin (high-AGE-BSA) was significantly
recognized by human monocyte-derived macrophages and Chinese hamster ovary cells which overexpress such scavenger receptors as CD36, SR-
BI (scavenger receptor class B type-I), and LOX-1 (Lectin-like Ox-LDL receptor-1), the mildly-modified-AGE-BSA (mild-AGE-BSA) did not
show any ligand activity to these cells. Furthermore, when 111In-labeled high- or mild-AGE-BSAwere injected into the tail vein of mice, the high-
AGE-BSA was rapidly cleared from the circulation whereas the clearance rate of the mild-AGE-BSA was very slow, similar to the native BSA.
These results demonstrate the first evidence that the ligand activity of the AGE-proteins to the scavenger receptors and its pharmacokinetic
properties depend on their rate of modification by AGEs, and we should carefully prepare the AGE-proteins in vitro to clarify the physiological
significance of the interaction between the AGE-receptors and AGE-proteins.
© 2007 Elsevier B.V. All rights reserved.Keywords: Advanced glycation end products (AGEs); Nε-(carboxymethyl)lysine (CML); Scavenger receptor; Macrophage; Atherosclerosis; Diabetes1. Introduction
The interaction between proteins modified with advanced
glycation end-products (AGEs) and the scavenger receptor(s) of
macrophages and smooth muscle cells is known to induce the
production of several cytokines such as plasminogen activator
and transforming growth factor-beta [1]. Furthermore, glycolal-
dehyde-derived AGE-low-density lipoprotein (AGE-LDL)
induces foam cell formation from macrophages [2]. TheseAbbreviations: AGE(s), advanced glycation end products; BSA, Bovine
serum albumin; High-AGE-BSA, highly modified AGE-BSA; Mild-AGE-BSA,
Mildly modified AGE-BSA; GA-AGE-BSA, Glycolaldehyde-derived AGE-
BSA; MALDI-TOFMS, Matrix Assisted Laser Desorption/Ionization-Time of
Flight Mass Spectrometry; CML, Nε-(carboxymethyl)lysine; ELISA, enzyme-
linked immunosorbent assay; PBS, phosphate-buffered saline
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doi:10.1016/j.bbadis.2007.09.001findings suggest the role of the AGE-modified proteins and
lipoproteins in the pathogenesis of atherosclerosis. However,
AGE-proteins are prepared in each research group independently
with different protocols, and all researchers, including our group,
use excessively high concentrations of glucose and aldehydes.
For instance, we prepared highly-modified AGE-bovine serum
albumin (high-AGE-BSA) by incubating BSA with 1600 mM
glucose for 40 weeks, or 33 mM glycolaldehyde for 7 days [3],
and demonstrated that high-AGE-BSA is recognized by SR-A
(class A scavenger receptor types I and II) [4], CD36 [5], SR-BI
(scavenger receptor class B type-I) [6], and LOX-1 (Lectin-like
Ox-LDL receptor-1) [7]. Schmidt et al. demonstrated that AGE-
BSA, prepared by incubating BSA with 250 mM glucose-6-
phosphate for 4 weeks, is recognized by RAGE (receptor for
AGE) [8] and the cellular interactions of AGEs with RAGE are
known to induce several cellular phenomena including the
expression of vascular cell adhesion molecule-1 (VCAM-1) in
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and her colleagues prepared AGE-BSA by incubating BSAwith
50 mM glucose-6-phosphate for 6 weeks [11] and demonstrated
that AGE-receptor 1 (AGER1), a 50-kDa type A integral
membrane protein with a short internal domain, suppresses cell
oxidant stress and activation signaling via the EGF receptor [12].
Furthermore, Takeuchi et al. also demonstrated that AGE-BSA
prepared using an unphysiologically high concentration of
glyceraldehydes results in toxicity to the vascular wall cells and
cortical neurons [13]. Taken together, those reports demonstrate
that the AGE-proteins were prepared with unphysiologically high
concentrations of aldehydes and then were employed for the
cellular experiments. However, little is known about the
correlation of the ligand activity of AGE-proteins and its rate of
modification. In the present study we prepared mildly modified
AGE-BSA (mild-AGE-BSA) by incubating BSA with 50 mM
glucose for 24 weeks, and then compared its ligand activity with
high-AGE-BSA against the scavenger receptors.
2. Materials and methods
2.1. Chemicals
D-glucose was purchased from Sigma-Aldrich Japan (Tokyo). Fatty acid-free
bovine serum albumin (BSA) was purchased from Wako (Osaka, Japan).
Lipopolysaccharide (LPS) from Escherichia coli was purchased from Sigma-
Aldrich Japan (Tokyo). Na 125I was obtained from Amersham Biosciences
(Arlington Heights, IL). Tissue culture medium was from Gibco BRL (NY, USA).
All other chemicals were of the best grade available from commercial sources.
2.2. Preparation of AGE-modified BSA
High-AGE-BSAwas prepared as described previously [1,3]. Briefly, 0.2 g/
ml of fatty acid-free BSAwas dissolved in 0.5 M sodium phosphate buffer (pH
7.4) with 1.6 M of D-glucose, sterilized by ultrafiltration and incubated at 37 °C
for 40 weeks, followed by dialysis against PBS. Mild-AGE-BSAwas prepared
by incubating 0.05 g/ml of fatty acid-free BSA with 50 mM of glucose in a
0.05 M sodium phosphate buffer (pH 7.4) at 37 °C for 24 weeks, followed by
dialysis against PBS. The glycolaldehyde-derived AGE-BSA (GA-AGE-BSA)
was prepared by incubating 2 mg/ml of fatty acid-free BSAwith 30 mM of GA
in a 0.05 M sodium phosphate buffer (pH 7.4) at 37 °C for up to 7 days, and
aliquots of the samples were collected at 3 h, 6 h, 12 h, 24 h, 48 h, 96 h, and
168 h, followed by dialysis against PBS. The extent of lysine modification of the
proteins was determined by reaction with 2, 4, 6-trinitrobenzenesulphonic acid
as described previously [3].
2.3. Characterization of aldehyde-modified proteins
The lysine and Nε-(carboxymethyl)lysine (CML) contents in the AGE-BSA
and human lens samples were quantified by high performance liquid
chromatography (HPLC) after acid hydrolysis with 6 N HCl for 24 h at
110 °C, as described previously [14]. The molecular mass of the AGE-BSAwas
measured as described previously [15]. Briefly, 1 μl of the sample protein
solution (10 pmol/μl) in 0.1% aqueous trifluoroacetic acid (TFA) water was
applied on a sample spot in a steel plate slide and dried in a stream of warm air.
The matrix solution which contained 10 mg/ml 3,5-dimethoxy-4-hydroxycin-
nanic acid (sinapinic acid) (Sigma-Aldrich Japan) in 50% vol/vol ethanol in
0.1% vol/vol TFAwas applied on a dried sample spot then dried in a stream of
warm air again. The molecular mass of the sample was analyzed by Matrix
Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry
(MALDI-TOFMS) (Shimadzu/Kratos Kompact MALDI III mass spectrometer,
Kyoto, Japan), operating in the positive high energy linear mode. An agarose gel
electrophoresis was performed using the Universal Gel/8 electrophoresis kit(Ciba-Corning, Tokyo), followed by staining with Coomassie brilliant blue.
Their electrophoretic mobilities relative to native BSA were expressed as the
relative electrophoretic mobility.
2.4. Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed as described previously [16]. Briefly, each well of a
96-well microtiter plate was coated with 100 μl of the sample to be tested in
PBS, blocked with 0.5% gelatin, and washed three times with PBS containing
0.05% Tween 20 (washing buffer). The wells were incubated with 0.1 ml of
monoclonal anti-AGE antibody (6D12: 0.5 μg/ml) dissolved in washing buffer
for 1 h. The wells were then washed with washing buffer three times and reacted
with HRP-conjugated anti-mouse IgG antibody, followed by reaction with 1,2-
phenylenediamine dihydrochloride. The reaction was terminated by the addition
of 0.1 ml of 1 M sulfuric acid, and the absorbance at 492 nm was read by a
micro-ELISA plate reader. We recently reported that 6D12 significantly
recognizes CML and Nε-(carboxyethyl)lysine [16].
2.5. Cellular assays
The modified BSA preparations were radiolabeled with 125I using Iodo-Gen
(Pierce, Rockford, IL) and dialyzed against PBS. The CHO cells overexpressing
CD36, SR-B1, or LOX-1 were maintained in Ham's F-12 medium containing
10% fetal calf serum and 0.5 mg/ml of G418 (medium A). For the uptake
experiments, these cells were seeded in a 24-well plate (8×104/well) and
cultured for 2 days in 1.0 ml of medium A, which was then replaced by medium
B (Dulbecco's modified Eagle's medium containing 3% BSA). Human
peripheral mononuclear cells were isolated from the blood of healthy volunteers
by Ficoll density gradient centrifugation (Ficoll-Paque, Amersham Bios-
ciences). The purified monocytes were suspended in RPMI 1640 and seeded
in a 24-well plate (5×105 cells/well) and incubated for 1 h. The monolayers thus
formed were washed three times with 1.0 ml of PBS. The cells were incubated
for 7 days to differentiate into macrophages and then replaced by medium B for
the uptake experiments [17]. The cells in each well were incubated at 37 °C for
8 h in 0.5 ml of medium B with three different concentrations of 125I-high-AGE-
BSA or 125I-mild-AGE-BSA, in the presence or absence of their 50-fold
unlabeled ligands. To measure the cell-associated radioactivity, each well was
washed twice with 1.0 ml of ice-cold PBS containing 1% BSA and two more
times with ice-cold PBS. The cells were lysed with 1.0 ml of 0.1 N sodium
hydroxide for 1 h at 37 °C to determine the cell-bound radioactivity and cellular
proteins. The protein concentration was measured by bicinchoninic acid protein
assay reagent (Pierce). The radioactivity of the sample was determined by
gamma counter (ARC 360, Aloka, Tokyo, Japan). The specific association and
degradation were determined by subtracting the nonspecific value from the total
value [3].
2.6. Human lens samples
The human cataract lens samples were obtained after receiving the approval
of the institutional review board of Shinshu University and Kumamoto
University and obtaining informed consent from all patients. The fragments of
lenses with cataract (8 from diabetes and 9 from non-diabetes) were collected
while surgery, and then the protein concentration of the sample was measured
with bicinchoninic acid protein assay reagent (Pierce, Rockford, IL). The CML
content of each sample was measured by an amino acid analysis as described
above.
2.7. Clearance experiments
The experimental protocol was approved by the local ethics review
committee for animal experimentation. The BSA, mild-AGE-BSA, and high-
AGE-BSAwere radiolabeled with 111In using the bifunctional chelating reagent
Diethylenetriamine-N,N,N′,N′′,N′′-pentaacetic acid (DTPA) anhydride, accord-
ing to the method of Hnatowich et al. [18]. The mice received tail vein injections
of 111In-labeled proteins in saline, at a dose of 1 mg/kg. At the appropriate
intervals after the injection, blood was collected from the vena cava under
anesthesia, and plasma was obtained by centrifugation. The organs were
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measured in a well-type NaI scintillation counter (ARC-500, Aloka, Tokyo). In
this study, the radioactivity of all samples and that of the plasma was normalized
to the percentage of dose. The plasma concentrations were analyzed by a
biexponential function using the non-linear least-squares computer program
MULTI [19]. The two-compartment model was fitted according to the Akaike
information criterion. The tissue distribution patterns were evaluated using
tissue uptake clearances (CLuptake) according to the integration plot analysis.
CLuptake was calculated by:
CLuptake ¼ Xt=CtAUC0t=Ct
where Xt is the tissue accumulation at time t, AUC0−t is the area under the
plasma concentration time-curve from time 0 to t, and Ct is the plasma
concentration at time t. CLuptake was obtained from the slope of the plot of Xt/Ct
versus AUC0−t/Ct. Each data point represents the mean±SD for three mice.
2.8. Statistical analysis
All of the experimental data are expressed as the mean±SD. The differences
between groups were examined for statistical significance using either Student's
t-test or one-way analysis of variance (ANOVA) with the Newman–Keuls post-
hoc test. A P value less than 0.05 was considered to denote the presence of a
statistically significant difference.Fig. 1. Physicochemical properties of AGE-BSA. A MALDI-TOFMS analysis of nati
of the sample was analyzed by MALDI III mass spectrometer. (D) Agarose gel electro
subjected to agarose gel electrophoresis and stained with Coomassie brilliant blue. T
electrophoretic mobility. (E) The reactivity of mild- and high-AGE-BSA with 6D123. Results and discussions
3.1. Physicochemical properties of AGE-BSA
We firstmeasured the increase in themolecularweight ofAGE-
BSA by a MALDI TOF mass analysis. As shown in Fig. 1A–C,
themolecular mass ofmild- and high-AGE-BSAwere 658Da and
9389 Da, respectively, and were larger than the native BSA. The
net negative charge of AGE-BSAwas determined by an agarose
gel electrophoresis. The electrophoretic mobility of the high-
AGE-BSA toward the anode was significantly higher than that of
the unmodified BSA, whereas the mild-AGE-BSA slightly
increased its mobility (Fig. 1D). Therefore, it is likely that the
increase in the molecular weight and the negative charge of the
high-AGE-BSAwas strikingly higher than that of the mild-AGE-
BSA. We next measured the reactivity of 6D12 to AGE-BSA. As
shown in Fig. 1E, 6D12 significantly recognized both the high-
and mild-AGE-BSA.
In the next step, the AGE-BSA and the human lens samples
were subjected to HPLC to compare the content of CML, a
major AGE structure, between the physiological samples and
the AGE-BSA, which was prepared in vitro. For this purpose,ve BSA (A), mild-AGE-BSA (B), and high-AGE-BSA (C). The molecular mass
phoresis of AGE-BSA. Native BSA, mild-AGE-BSA, and high-AGE-BSAwere
heir electrophoretic mobilities relative to native BSAwere expressed as relative
was determined by ELISA.
Table 1
Comparison of the CML content in the samples by HPLC
Samples mmol CML/mol Lys
High-AGE-BSA 618.6
Mild-AGE-BSA 24.4
Diabetic lenses, n=8 17.4±3.8
Non-diabetic lenses, n=9 8.6±2.1
The samples were hydrolyzed with 6 N HCl for 24 h at 110 °C and then were
subjected to HPLC. The amount of CML content was normalized to the lysine
content of the sample. Data are mean±SD.
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AGE accumulation are observed in the long-lived proteins such
as the lens proteins [20]. Table 1 summarizes the CML content
in the samples. The CML content for the high- and mild-AGE-
BSAwere 618.6 mmol CML/mol Lys and 24.4 mmol CML/mol
Lys, respectively. However, the CML contents for the diabetic-
and non-diabetic human lens samples were ∼17.4 mmol /mol
Lys and ∼8.6 mmol/mol Lys, respectively, thus indicating that
our experimentally prepared mild-AGE-BSAwas already more
profoundly modified than physiological samples.
3.2. Ligand activity of AGE-BSA to human monocyte-derived
macrophages and CHO cells overexpressing scavenger
receptors
We next determined whether the high- and mild-AGE-BSA
preparations could interact with cells as ligands. As shown inFig. 2. Ligand activity of AGE-BSA to human monocyte-derived macrophages and
BSA by human monocyte-derived macrophages and CHO cells which overexpress C
CHO (B), CD36-CHO (C), and LOX-1-CHO (D) cells were incubated at 37 °C fo
or 125I-mild-AGE-BSA (open circles) in the presence or absence of their 50-fold
125I-mild-AGE-BSA were calculated by correcting for nonspecific cell associations.Fig. 2A, the 125I-high-AGE-BSAwas specifically associated in
a dose-dependent manner, whereas these changes were not
observed in the 125I-mild-AGE-BSA. Similar tendencies were
observed in the CHO overexpressing scavenger receptors.
Therefore, the 125I-high-AGE-BSA was specifically associated
with the CHO cells overexpressing SR-BI (Fig. 2B), CD36
(Fig. 2C), and LOX-1 (Fig. 2D), whereas the association of the
125I-mild-AGE-BSA to these cells was negligible, and thereby
strongly demonstrated that only the high-AGE-BSA showed
ligand activity to the scavenger receptors.
3.3. Plasma clearance and organ distribution of AGE-BSA
Fig. 3 shows the plasma clearance and organ distribution in
the mice that had been intravenously injected with 111In-BSA,
111In-mild-AGE-BSA, and 111In-high-AGE-BSA. The plasma
clearance rates of 111In-mild-AGE-BSAwere very slow, similar
to the 111In-BSA, whereas the radioactivity of 111In-high-AGE-
BSA was rapidly cleared from the circulation, with about 90%
of the injected 111In-high-AGE-BSA being eliminated within
5 min after the intravenous administration (Fig. 3A). At 120 min
after the intravenous injection of 111In-high-AGE-BSA, the
organ distribution was 60% for the liver, 1.5% for the spleen,
and 4% for the kidney, suggesting that the rapid disappearance
of the 111In-high-AGE-BSA from the plasma is accompanied by
a very pronounced increase in liver clearance (Fig. 3B–D). The
uptake clearance calculated using the nonlinear least-squaresCHO cells overexpressing scavenger receptors. The endocytic uptake of AGE-
D36, SR-BI, and LOX-1. Human monocyte-derived macrophages (A), SR-B1-
r 8 h with the indicated concentration of 125I-high-AGE-BSA (closed circles)
unlabeled ligands. The cells specific association of 125I-high-AGE-BSA and
Data are mean±SD, n=2.
Fig. 3. Plasma clearance and organ distribution of AGE-BSA after intravenous administration to mice. 111In-BSA (open circles), 111In-mild-AGE-BSA (closed
triangles), and 111In-high-AGE-BSA (closed squares) were injected as a bolus through the tail vein of mice, and the relative radioactivities were plotted against the time
after injection. Each data point represents the mean±SD for three mice.
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major role in the clearance of high-AGE-BSA (Table 2). The
accumulation by other organs such as the pancreas, lung, heart,
and brain was negligibly low, and the pattern was indistin-
guishable from that of BSA. Since the scavenger receptors such
as SR-A and SR-BI are highly expressed in the liver [21], it is
reasonable to conclude that the high-AGE-BSA is endocytosed
in the liver. In contrast, the clearance rate of the 111In-mild-
AGE-BSA was very slow in comparison to the 111In-native
BSA (Fig. 3A). Smedsrod et al. [22] demonstrated that
intravenously injected 125I-high-AGE-BSA to rat rapidly
accumulated in liver and about 60% of 125I-high-AGE-BSA
was localized in endothelial cells. We also previously
demonstrated that isolated mice liver endothelial cells recognize
high-AGE-BSA as a ligand [23]. Those reports are correlated
with our present results. Therefore, high-AGE-BSA was
significantly recognized in the liver.
3.4. Correlation of the extents of lysine modification of
glycolaldehyde-derived AGE-BSA with their ligand activities
Since we previously demonstrated that high-AGE-BSA and
GA-AGE-BSA show the same ligand activity to the scavengerTable 2
Uptake clearance of AGE-BSA after intravenous administration to mice
(μL/h) Liver Kidney Spleen
BSA 57.5±13.1 44.4±1.9 12.6±4.8
Mild-AGE-BSA 273.3±53.8 199.1±33.0 21.9±11.6
High-AGE-BSA 35016.9±8554.4⁎,# 3185.3±689.6⁎,# 3983.8±964.4⁎,#
Data represent the mean±SD for three sets of experiments. ⁎Pb 0.001 versus
BSA. #Pb0.001 versus Mild-AGE-BSA.receptor [3], we next examined the correlation between the
extent of the lysine modification of GA-AGE-BSA and its
ligand activity to the scavenger receptor. For this purpose, we
prepared the GA-AGE-BSA samples with different lysine
modifications and the 125I-high-AGE-BSA was incubated with
RAW 264.7 cells in the presence of 50-fold unlabeled GA-
AGE-BSA with different lysine modification samples. As
shown in Fig. 4, although the association of 125I-high-AGE-
BSA to the cells was not inhibited in the presence of the 29%
lysine-modified unlabeled GA-AGE-BSA, it was significantly
inhibited in the presence of N49% lysine-modified unlabeled
GA-AGE-BSA, demonstrating that high lysine-modification is
required to be a ligand for the scavenger receptor. Furthermore,Fig. 4. Correlation of the extents of lysine modification of GA-AGE-BSAwith
their ligand activities. RAW 264.7 cells were incubated at 37 °C for 8 h with
1.25 μg/ml of 125I-high-AGE-BSA in the presence of 50-fold unlabeled GA-
AGE-BSA with different lysine modification samples. The cell association of
125I-high-AGE-BSA was plotted against the extent of lysine modification of
competitor GA-AGE-BSA. Data are mean±SD, n=2. ⁎, Pb0.05, ⁎⁎, Pb0.01
vs. unmodified BSA.
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RAW 264.7 cells for 6 h in the presence of 50-fold ex-
cess amount of human lens samples. Although association of
125I-GA-AGE-BSAwas inhibited by unlabeled GA-AGE-BSA,
mild-AGE-BSA and human lens samples did not show any
inhibitory effect, thus indicating that physiological AGE-
samples do not show any ligand activity to the scavenger
receptors. Although we previously removed LPS from AGE-
BSA by polylysine-conjugated sepharose column chromatog-
raphy, we stopped removing LPS because the ligand activity of
AGE-BSA to scavenger receptor does not change at all before
and after removal of LPS. In fact, although association of 125I-
GA-AGE-BSA to RAW 264.7 cells was inhibited by unlabeled
GA-AGE-BSA, the addition of 1–100 pg/ml of LPS did not
show any inhibitory effect (Fig. 5). In the present study, we paid
attention to using the fatty acid-free BSA instead of low-
endotoxin BSA because Fu MX et al. [24] reported that CML is
also generated from fatty acids such as arachidonate and
linoleate, and thus may affect the ligand activity to scavenger
receptors.
Immunohistochemical studies have demonstrated that GA-
pyridine, one of the myeloperoxidase-derived AGEs through
glycolaldehyde, was predominantly accumulated in the cyto-
plasm of the foam cells in human atherosclerotic lesions [25],
thus indicating that GA-pyridine detected in foam cells may be
generated within the cells. Regarding the AGE formation inside
cells, Hammes et al. [26] reported that thiamine and
benfotiamine prevent the intracellular AGE formation by
reducing the concentration of methylglyoxal, a strong AGE-
precursor, and hence inhibit diabetic retinopathy. In the case of
the glycated-proteins presence in vivo, Thornalley et al. [15]
demonstrated that end-stage renal disease is associated with a
significant increase in the molecular mass of HSA (+255 Da,
relative to the control subjects) and ∼3% of lysine residues
were modified. However, our study using a MALDI-TOFMS
analysis demonstrated that the molecular mass of the mild-
AGE-BSA was 658 Da larger than the native BSA (Fig. 1B),Fig. 5. Inhibitory effect of human lens proteins on the association of GA-AGE-
BSA to RAW 264.7 cells. RAW 264.7 cells were incubated at 37 °C for 6 h
with 2 μg/ml of 125I-AGE-GA-BSA (82.5% of lysine residues were modified)
in the presence of 50-fold unlabeled diabetic human lens samples, GA-AGE-
BSA or mild-AGE-BSA. LPS was also used at 1–100 pg/ml. The CML
content of diabetic lens samples case #6 and #8 were 19.6 and 16.8 mmol
CML/mol Lys, respectively. Amounts of cell-associated 125I-AGE-GA-BSA
were determined as described in Materials and methods. Data are mean±SD,
n=2.indicating that our experimentally prepared mild-AGE-BSA is
already more profoundly modified than physiological human
serum albumin under (patho)physiological conditions. Further-
more, although only ∼3% of lysine residues of HSA were
modified in dialysis patient [15], N49% lysine-modification is
required to be a ligand for the scavenger receptor (Fig. 4). Taken
together, our results demonstrate that the endocytic uptake of
physiologically generated AGE-proteins through scavenger
receptors is either negligible or unlikely to occur in vivo, and
that AGEs detected inside foam cells in atherosclerotic lesions
are generated intracellularly rather than representing the
endocytic uptake of extracellular AGE-proteins by the scaven-
ger receptors. Although most other researchers prepare the
AGE-proteins with unphysiologically high concentrations of
aldehydes and then are employed for the cellular experiments,
some researchers consider the issues and have also prepared
AGE-proteins with physiologically relevant concentrations of
glycating agents in order to perform cellular experiments. For
instance, macrophage-colony stimulating factor (M-CSF) is
released from mature human monocytes and human monocytic
THP-1 cells by incubating with HSA minimally-modified by
methylglyoxal (MGmin-HSA) and glucose (AGEmin-HSA) [27].
MGmin-HSA also induces the synthesis and secretion of tumor
necrosis factor-α (TNF-α) from human monocytic THP-1 cells
in vitro [28]. Furthermore, Xu et al. [29] demonstrated that
mildly-modified AGE-BSA which was prepared by incubating
50 mM glucose inhibits nitric oxide synthesis of human
endothelial cells, indicating that several cellular interactions
take place even AGE-proteins with physiologically relevant
concentrations of glycating agents. These results suggest that
mildly modified AGE-proteins may be recognized by AGE
receptors such as RAGE and induce several cellular responses
in vivo. This study demonstrates the first evidence that the
ligand activity of the AGE-proteins to the scavenger receptors is
dependent on their rate of modification by the AGEs, and we
should carefully prepare the AGE-proteins in vitro to clarify the
physiological significance of the interaction between the AGE-
receptors and AGE-proteins.
Acknowledgments
This work was supported in part by a Grant-in-Aid for
scientific Research (No. 18790619 to Ryoji Nagai) from the
Ministry of Education, Science, Sports and Cultures of Japan.
References
[1] T. Higashi, H. Sano, T. Saishoji, K. Ikeda, Y. Jinnouchi, T. Kanzaki, N.
Morisaki, H. Rauvala, M. Shichiri, S. Horiuchi, The receptor for advanced
glycation end products mediates the chemotaxis of rabbit smooth muscle
cells, Diabetes 46 (1997) 463–472.
[2] Y. Jinnouchi, H. Sano, R. Nagai, H. Hakamata, T. Kodama, H. Suzuki, M.
Yoshida, S. Ueda, S. Horiuchi, Glycolaldehyde-modified low density
lipoprotein leads macrophages to foam cells via the macrophage scavenger
receptor, J. Biochem. (Tokyo) 123 (1998) 1208–1217.
[3] R. Nagai, K. Matsumoto, X. Ling, H. Suzuki, T. Araki, S. Horiuchi,
Glycolaldehyde, a reactive intermediate for advanced glycation end
products, plays an important role in the generation of an active ligand for
the macrophage scavenger receptor, Diabetes 49 (2000) 1714–1723.
1198 R. Nagai et al. / Biochimica et Biophysica Acta 1772 (2007) 1192–1198[4] H. Suzuki, Y. Kurihara, M. Takeya, N. Kamada, M. Kataoka, K. Jishage,
O. Ueda, H. Sakaguchi, T. Higashi, T. Suzuki, Y. Takashima, Y. Kawabe,
O. Cynshi, Y. Wada, M. Honda, H. Kurihara, H. Aburatani, T. Doi, A.
Matsumoto, S. Azuma, T. Noda, Y. Toyoda, H. Itakura, Y. Yazaki, T.
Kodama, et al., A role for macrophage scavenger receptors in athero-
sclerosis and susceptibility to infection, Nature 386 (1997) 292–296.
[5] N. Ohgami, R. Nagai, M. Ikemoto, H. Arai, A. Kuniyasu, S. Horiuchi, H.
Nakayama, Cd36, a member of the class b scavenger receptor family, as a
receptor for advanced glycation end products, J. Biol. Chem. 276 (2001)
3195–3202.
[6] N. Ohgami, R. Nagai, A. Miyazaki, M. Ikemoto, H. Arai, S. Horiuchi, H.
Nakayama, Scavenger receptor class B type I-mediated reverse cholesterol
transport is inhibited by advanced glycation end products, J. Biol. Chem.
276 (2001) 13348–13355.
[7] T. Jono, A. Miyazaki, R. Nagai, T. Sawamura, T. Kitamura, S. Horiuchi,
Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as
an endothelial receptor for advanced glycation end products (AGE), FEBS
Lett. 511 (2002) 170–174.
[8] A.M. Schmidt, M. Vianna, M. Gerlach, J. Brett, J. Ryan, J. Kao, C.
Esposito, H. Hegarty, W. Hurley, M. Clauss, et al., Isolation and
characterization of two binding proteins for advanced glycosylation end
products from bovine lung which are present on the endothelial cell
surface, J. Biol. Chem. 267 (1992) 14987–14997.
[9] A.M. Schmidt, O. Hori, J.X. Chen, J.F. Li, J. Crandall, J. Zhang, R. Cao,
S.D. Yan, J. Brett, D. Stern, Advanced glycation endproducts interacting
with their endothelial receptor induce expression of vascular cell adhesion
molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A
potential mechanism for the accelerated vasculopathy of diabetes, J. Clin.
Invest. 96 (1995) 1395–1403.
[10] K. Ichikawa, M. Yoshinari, M. Iwase, M. Wakisaka, Y. Doi, K. Iino, M.
Yamamoto, M. Fujishima, Advanced glycosylation end products induced
tissue factor expression in human monocyte-like U937 cells and increased
tissue factor expression in monocytes from diabetic patients, Atheroscle-
rosis 136 (1998) 281–287.
[11] H. Vlassara, H. Fuh, Z. Makita, S. Krungkrai, A. Cerami, R. Bucala,
Exogenous advanced glycosylation end products induce complex vascular
dysfunction in normal animals: a model for diabetic and aging
complications, Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 12043–12047.
[12] W. Cai, J.C. He, L. Zhu, C. Lu, H. Vlassara, Advanced glycation end
product (AGE) receptor 1 suppresses cell oxidant stress and activation
signaling via EGF receptor, Proc. Natl. Acad. Sci. U. S. A. 103 (2006)
13801–13806.
[13] M. Takeuchi, S. Yamagishi, Alternative routes for the formation of
glyceraldehyde-derived AGEs (TAGE) in vivo, Med. Hypotheses 63 (2004)
453–455.
[14] R. Nagai, Y. Unno, M.C. Hayashi, S. Masuda, F. Hayase, N. Kinae, S.
Horiuchi, Peroxynitrite induces formation of N( epsilon )-(carboxymethyl)
lysine by the cleavage of Amadori product and generation of glucosone
and glyoxal from glucose: novel pathways for protein modification by
peroxynitrite, Diabetes 51 (2002) 2833–2839.
[15] P.J. Thornalley, M. Argirova, N. Ahmed, V.M. Mann, O. Argirov, A.
Dawnay, Mass spectrometric monitoring of albumin in uremia, Kidney Int.
58 (2000) 2228–2234.[16] W. Koito, T. Araki, S. Horiuchi, R. Nagai, Conventional antibody against
Nepsilon-(carboxymethyl)lysine (CML) shows cross-reaction to Nepsilon-
(carboxyethyl)lysine (CEL): immunochemical quantification of CML with
a specific antibody, J. Biochem. (Tokyo) 136 (2004) 831–837.
[17] K. Fukuhara-Takaki, M. Sakai, Y. Sakamoto, M. Takeya, S. Horiuchi,
Expression of class A scavenger receptor is enhanced by high glucose in
vitro and under diabetic conditions in vivo: one mechanism for an increased
rate of atherosclerosis in diabetes, J. Biol. Chem. 280 (2005) 3355–3364.
[18] D.J. Hnatowich, W.W. Latne, R.L. Childs, The preparation and labeling of
DTPA-coupled albumin, Int. J. Appl. Isot. 33 (1982) 327–332.
[19] K. Yamaoka, Y. Tanigawara, T. Nakagawa, T. Uno, A pharmacokinetic
analysis program (multi) for microcomputer, J. Pharmacobio-Dyn. 4 (1981)
879–885.
[20] J.A. Dunn, J.S. Patrick, S.R. Thorpe, J.W. Baynes, Oxidation of glycated
proteins: age-dependent accumulation of N epsilon-(carboxymethyl)lysine
in lens proteins, Biochemistry 28 (1989) 9464–9468.
[21] S. Horiuchi, Y. Sakamoto, M. Sakai, Scavenger receptors for oxidized and
glycated proteins, Amino Acids 25 (2003) 283–292.
[22] B. Smedsrod, J. Melkko, N. Araki, H. Sano, S. Horiuchi, Advanced
glycation end products are eliminated by scavenger-receptor-mediated
endocytosis in hepatic sinusoidal Kupffer and endothelial cells, Biochem.
J. 322 (Pt 2) (1997) 567–573.
[23] K. Matsumoto, H. Sano, R. Nagai, H. Suzuki, T. Kodama, M. Yoshida, S.
Ueda, B. Smedsrod, S. Horiuchi, Endocytic uptake of advanced glycation
end products by mouse liver sinusoidal endothelial cells is mediated by a
scavenger receptor distinct from the macrophage scavenger receptor class
A, Biochem. J. 352 (Pt 1) (2000) 233–240.
[24] M.X. Fu, J.R. Requena, A.J. Jenkins, T.J. Lyons, J.W. Baynes, S.R.
Thorpe, The advanced glycation end product, Nepsilon-(carboxymethyl)
lysine, is a product of both lipid peroxidation and glycoxidation reactions,
J. Biol. Chem. 271 (1996) 9982–9986.
[25] R. Nagai, C.M. Hayashi, L. Xia, M. Takeya, S. Horiuchi, Identification in
human atherosclerotic lesions of GA-pyridine, a novel structure derived
from glycolaldehyde-modified proteins, J. Biol. Chem. 277 (2002)
48905–48912.
[26] H.P. Hammes, X. Du, D. Edelstein, T. Taguchi, T. Matsumura, Q. Ju, J.
Lin, A. Bierhaus, P. Nawroth, D. Hannak, M. Neumaier, R. Bergfeld, I.
Giardino, M. Brownlee, Benfotiamine blocks three major pathways of
hyperglycemic damage and prevents experimental diabetic retinopathy,
Nat. Med. 9 (2003) 294–299.
[27] E.A. Abordo, M.E. Westwood, P.J. Thornalley, Synthesis and secretion of
macrophage colony stimulating factor by mature human monocytes and
human monocytic THP-1 cells induced by human serum albumin
derivatives modified with methylglyoxal and glucose-derived advanced
glycation endproducts, Immunol. Lett. 53 (1996) 7–13.
[28] E.A. Abordo, P.J. Thornalley, Synthesis and secretion of tumour necrosis
factor-alpha by human monocytic THP-1 cells and chemotaxis induced by
human serum albumin derivatives modified with methylglyoxal and
glucose-derived advanced glycation endproducts, Immunol. Lett. 58 (1997)
139–147.
[29] B. Xu, Y. Ji, K. Yao, Y.X. Cao, A. Ferro, Inhibition of human endothelial
cell nitric oxide synthesis by advanced glycation end-products but not
glucose: relevance to diabetes, Clin. Sci. (Lond) 109 (2005) 439–446.
